Penumbra Inc · Health Care
$322.80
As of: 2026-09-03 01:42:38 (KST)
-39.1%
Expected return
28%
Success probability
-42.4%
Downside risk
For informational purposes only.
Not investment advice.
Penumbra Inc in the Health Care industry carries C grade, driven by a Monte Carlo rating of 15. With an expected return of -39.1% and a 28% chance of positive returns, the stock at $322.80 presents This assessment is based on 10,000 probabilistic scenarios, offering a robust view of the potential return distribution across varying market conditions.
The Reverse DCF analysis places this stock in the "Expensive" zone. The implied growth rate (g_implied) of 77.1%, compared with the actual growth rate of 16.8%, reveals the market's pricing assumptions. The P50 intrinsic value sits at $200, offering a reference point against the current price. At $324, the Reverse-DCF implied probability of finishing above $324 stands at 0%.
This C rating (15) suggests caution. The expected return of -39.1% and 28% success probability are below our threshold for an attractive entry.
The Monte Carlo distribution reveals a volatility of 2.9% — relatively low, meaning the simulated outcomes cluster tightly around the median. The P50 sits at -39.5%, with a +4.8% gap between P10 (-42.4%) and P75 (-37.6%). a negative skew suggests downside scenarios are more pronounced than upside ones
In the worst 5% of scenarios, the 5th percentile value-at-risk is -42.4%. On the operating side, at 12.4%, operating margins are adequate but could compress under competitive pressure. With a volatility of 2.9%, volatility risk is low at the current price of $323.
DCF estimates a company's intrinsic value by discounting its future cash flows to present value. Modelvix uses Monte Carlo simulation to analyze thousands of scenarios.
Learn more →WACC is the average rate a company pays to finance its assets, used as the discount rate in DCF analysis. Modelvix simulates how WACC changes affect valuation.
Learn more →Terminal value represents the perpetual value of a business beyond the forecast period, often comprising the majority of DCF value. Modelvix analyzes terminal value uncertainty across growth scenarios.
Learn more →Reverse DCF works backward from the current stock price to infer the growth rate the market expects, helping you assess whether a stock is fairly valued. Modelvix shows what growth assumptions the current price implies.
Learn more →